The distribution of activating mutations, with RAS gene mutations occurring not only in NRAS but also KRAS, and NF1 mutations being frequent in tumours lacking BRAF or RAS mutations, suggests that the proposed genetic classification of cutaneous melanomas into BRAF-mutated, RAS-mutated, NF1-mutated or triple-wild-type tumours is also applicable to conjunctival melanoma. This evidence concerns the gene KRAS and neoplasm.